Alyeska Investment Group, L.P. An2 Therapeutics, Inc. Transaction History

Alyeska Investment Group, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.78 - $21.53 $139,000 - $1.08 Million	50,000 Added 100.0%	100,000 $325,000
Q4 2023 Feb 14, 2024	SELL	$13.92 - $21.0 $674,089 - $1.02 Million	-48,426 Reduced 49.2%	50,000 $1.02 Million
Q2 2023 Aug 14, 2023	BUY	$5.06 - $9.91 $252,999 - $495,500	50,000 Added 103.25%	98,426 $836,000
Q4 2022 Feb 14, 2023	SELL	$8.51 - $19.69 $487,554 - $1.13 Million	-57,292 Reduced 54.19%	48,426 $461,000
Q3 2022 Nov 14, 2022	SELL	$7.61 - $22.29 $146,736 - $429,795	-19,282 Reduced 15.43%	105,718 $1.84 Million
Q1 2022 May 16, 2022	BUY	$15.0 - $15.4 $1.88 Million - $1.93 Million	125,000 New	125,000 $1.88 Million

13.5M

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $24.4M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.